Our story
BetaGlue is an Italian biotech company developing next-generation nuclear therapies for solid tumors.
Born at the crossroads of biotechnology, radiochemistry, and interventional oncology, BetaGlue was founded with a single purpose: to turn nuclear science into targeted, effective treatments for cancers with limited therapeutic options.
From our headquarters in Italy, we collaborate with clinicians, scientists, and partners across Europe and the U.S. to bring innovative radiotherapeutics closer to patients who need them most.
Our science
Targeted nuclear medicine, redefined.
BetaGlue’s platform delivers radiation precisely where it matters most — inside the tumor.
Our lead program, YntraDose, enables interventional oncologists to deposit a therapeutic payload of beta-emitting isotopes directly within the tumor mass. This localized delivery aims to maximize tumour control while minimizing systemic exposure, making it a promising solution for pancreatic cancer and other hard-to-treat solid tumours.
Our approach
Scientific excellence
Driven by rigorous clinical research, advanced materials science, and strong collaborations with leading academic centers.
Translational innovation
Bridging nuclear physics, radiochemistry, and medical devices into a single, integrated therapeutic solution.
Real-world focus
Designing every therapy to fit seamlessly into current clinical practice, enabling fast adoption and measurable patient benefit.
Our partnerships
Collaborating to accelerate innovation.
BetaGlue partners with pharmaceutical companies, interventional radiology networks, and academic hospitals to advance clinical research, co-develop combination therapies, and scale manufacturing capabilities. Together, we aim to build the next generation of targeted radiotherapeutics that integrate seamlessly into modern cancer care.
Our vision
To establish BetaGlue as a reference innovator in nuclear oncology, delivering precision radiotherapeutics that transform the treatment paradigm for solid tumors. We are committed to a future where radiation is not only powerful but precise, localized, and life-changing.
Our leadership
Our multidisciplinary team combines expertise from nuclear medicine, oncology, medical devices, and regulatory affairs.
Together, we bring a rare mix of scientific depth, operational rigor, and entrepreneurial agility, ensuring that BetaGlue moves from discovery to clinical proof with speed and quality.
Join us
Whether you are a pharma company, a radiology technology partner, or an investor seeking breakthrough innovation in healthcare, BetaGlue welcomes collaboration.
Together, we can turn precision science into meaningful patient impact.